Actively Recruiting
Open-Label Study of Nasal Foralumab for Adults With Non-Active Secondary Progressive Multiple Sclerosis 6-Month Treatment Following Completion of Prior Phase 2a Study
Led by Tiziana Life Sciences LTD · Updated on 2025-06-06
55
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating nasal foralumab in patients with non-active secondary progressive multiple sclerosis SPMS who have completed a prior Phase 2a study called TILS-021. This open-label extension study, TILS-022, aims to assess the safety and clinical effects of nasal foralumab over six months, with a possibility of dose escalation based on clinical status. The study focuses on safety, neurological assessments, fatigue impact, and immunologic changes in a controlled clinical setting. Participants begin the study receiving nasal foralumab at a dose of 50 micrograms three times a week Monday, Wednesday, and Friday for two weeks, followed by a one-week break, repeating in 3-week cycles. At week 12, the dose may be increased to 100 micrograms following specific dose escalation rules. This design allows all participants from the prior placebo-controlled trial to receive the active treatment openly for six months, with potential for extended treatment pending regulatory review. During the study, participants undergo regular clinical and laboratory evaluations including neurological exams, nasal symptom scoring, and fatigue assessments using standardized scales. Safety monitoring includes adverse event tracking and lab tests throughout the 169-day treatment period. Researchers will compare baseline and end-of-study measures to evaluate tolerability and clinical effects. The total participation duration is six months, with future study extension possibilities under consideration.
CONDITIONS
Brief Title
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Research Team
T
Tiziana
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here